Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Feb 5 (Reuters) - Bristol-Myers Squibb Co reported a quarterly loss due to a charge it took related to recent U.S. tax law changes, and said a late-stage trial testing its immunotherapy Opdivo in patients with a common type of lung cancer met its main goal.

Fourth-quarter net loss attributable came in at $2.33 billion compared with a year-ago profit of $894 million, as the drugmaker took a $2.9 billion charge.

Bristol-Myers in October said it expects to have final data in the first half of 2018 from a key trial of Opdivo as a treatment for newly diagnosed lung cancer patients.

(Reporting by Manas Mishra in Bengaluru; Editing by Martina D'Couto)

Source : https://finance.yahoo.com/news/bristol-myers-says-key-trial-121034744.html

240
Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Source:Forbes

Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Source:Reuters

Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Source:Reuters

Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds

Source:Reuters

Bristol Myers Says Key Trial For Lung Cancer Drug Succeeds